Menü Logo

The significance of early treatment of exudative age-related macular degeneration: 12 months' results.

<H4>BACKGROUND: </H4><P>To assess whether the period between initial symptoms and therapy with ranibizumab in patients with choroidal neovascularization (CNV) influences visual outcome after a follow-up of 12 months.</P><H4>METHODS: </H4><P>Fifty patients with CNV were retrospectively split into three groups depending on the duration of visual symptoms: group I: &lt;?1 month, group II: 1-6 months, and group III: &gt;?6 months. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were recorded at baseline, 2, 6, and 12 months. Patients received two initial intravitreal injections of 0.5&nbsp;mg ranibizumab at baseline and reinjections as needed.</P><H4>RESULTS: </H4><P>The mean time span between initial symptoms and treatment was 66?±?63 days. A longer duration of visual symptoms was significantly correlated with a lower BCVA at baseline, but also after 6 and 12 months.</P><H4>CONCLUSIONS: </H4><P>Shorter duration of visual symptoms prior to treatment is associated with a better visual outcome.</P>

Um den vollständigen Inhalt zu sehen, müssen Sie sich einloggen oder sich auf registrieren.

Jetzt einloggen

Passwort vergessen

Jetzt kostenlos registrieren

Mit einer Anmeldung bei haben Sie Zugriff auf: DFP-Kurse, Arzneimittelinfos, Produktfortbildungen und mehr.

Loggen Sie sich ein oder registrieren Sie Ihren kostenlosen Account.